Ellansé S and Ellansé M look almost too similar to justify two places in a clinic’s inventory. Both belong to the same PCL-and-CMC product platform, and Cytollia currently lists both in a 2 × 1 mL format. The letter on the box therefore invites an easy—but misleading—explanation: S must be the softer option and M the stronger one.
The published technical story is more useful. Ellansé’s expert guide attributes the longer duration of M to longer PCL polymer chains, not to a declared increase in concentration, particle size or “strength.” The clinic decision is whether the menu needs one duration commitment or two, and whether each can be explained and stocked without creating duplicate services.
Quick answer
Choose the duration horizon—not a strength tier
Ellansé S and M use the same core platform: smooth polycaprolactone (PCL) microspheres suspended in a carboxymethylcellulose (CMC) carrier gel. Published product literature links their different expected duration to the molecular chain length of the PCL inside the microspheres. The M chains are longer and take longer to degrade than the S chains.
S can support a shorter-duration service lane and M a longer-duration lane. Carrying both makes sense only when each answers different demand and can be quoted, recorded and reordered separately. M is not automatically better, and S is not automatically a “beginner filler.”
This guide compares product architecture, published duration evidence, current Cytollia pack format and clinic stocking logic. It does not assign injection areas, depths or doses, and it does not determine clinical superiority.
At a glance
The same platform supports two different commitment levels
| Decision field | Ellansé S | Ellansé M | What it means for a clinic |
|---|---|---|---|
| Core platform | PCL microspheres in a CMC-based carrier gel | PCL microspheres in a CMC-based carrier gel | The letters do not describe two different ingredient categories. |
| Documented variant difference | Shorter PCL polymer chains | Longer PCL polymer chains | The technical distinction is designed around degradation time and expected duration. |
| Duration evidence | Variant-specific studies include 12-month and 12–18-month follow-up | A 24-month randomized trial and other M-specific studies support the longer horizon | Use the relative difference for planning; do not promise an exact personal result. |
| Current Cytollia pack | 2 × 1 mL | 2 × 1 mL | Pack count does not create the distinction, and it does not define dose or number of services. |
| Current price position | Lower of the two live listings at verification | Higher of the two live listings at verification | Keep amounts on the live product pages; compare service horizon, not a frozen article price. |
| Clearer menu role | Shorter-duration commitment | Longer-duration commitment | Carry both only if the clinic can maintain two distinct consultation and inventory lanes. |
Variant architecture
Why S and M should not be taught as a strength ladder
A letter sequence naturally looks like a scale. Teams may turn that scale into scripts such as “S is light” and “M is strong,” then extend the assumption into texture, lifting power or treatment area. The official device description does not support that shortcut. Sinclair’s current safety and clinical summary identifies S and M as variants of the same PCL-microsphere and CMC-carrier device.
The manufacturer’s expert guide is more specific: the PCL chains in M are longer than those in S, and the difference in duration is due to that difference in chain length and molecular weight. It does not describe M as a higher-concentration version, nor does it say the letter alone creates a universal area map.
A defensible explanation
“M has the longer duration design”
This keeps the discussion attached to the documented variant architecture and lets the professional assess whether that horizon fits the individual client.
An avoidable shortcut
“M is stronger and goes deeper”
This converts a duration code into rheology and technique claims the letter does not establish. It is easy to remember, but it is not a reliable product explanation.
Product DNA
What actually changes between the two variants
Peer-reviewed descriptions of Ellansé report 30% smooth PCL microspheres in 70% aqueous CMC carrier gel. CMC provides the initial filling component, while PCL is associated with the longer-term collagen response. That shared mechanism explains the close family resemblance.
The tunable variable is the polymer. PCL degrades by hydrolysis: its chains become shorter over time until smaller fragments can be broken down and eliminated. Ellansé’s technical guide states that M starts with longer PCL chains than S, so the degradation process takes longer. This is a time-design difference inside the microsphere—not evidence that M contains more product or larger particles.
If a quotation, stock record or client document says only “Ellansé,” the clinic has lost the field that distinguishes the two services. The exact S or M variant should remain visible throughout ordering and record keeping.
Duration Evidence Ladder
“S versus M” is reliable; a guaranteed month count is not
The search result most people want is a simple number. The evidence supports a relative answer more confidently than a universal clock.
The clean consultation statement is therefore: M is designed and evidenced for a longer expected duration than S; the exact duration should remain an expectation range, not a promise.
Clinic Fit Map
Match the SKU to the service commitment your clinic can support
Stocking Snapshot
Should the clinic order S, M or both?
Two SKUs should represent two repeatable jobs. Before carrying both, test the menu.
- Demand: are clients and practitioners asking for two duration horizons, or will one option dominate?
- Explanation: can the team explain “shorter versus longer” without turning it into “weak versus strong”?
- Traceability: will quotes, orders and client records preserve the exact S or M variant?
- Turnover: can two similar 2 × 1 mL products rotate without one becoming duplicate stock?
S only
Keep the commitment shorter
Coherent when the clinic wants one PCL SKU, a shorter horizon and simpler training. This is a menu choice, not a rule for new clients.
M only
Build around the longer horizon
Coherent when longer-duration demand exists and the team can explain, price and document the commitment.
S + M
Offer two deliberate lanes
Worthwhile when duration preference changes the consultation. If both use the same name and script, one may become duplicate stock.
Commercial decision
Use live price position without freezing a price into the guide
Cytollia’s current listings place M above S in price. The article should not reproduce the amounts: tier pricing and catalogue prices can change, while the editorial reason for the gap remains the longer-duration positioning of M.
Use this guide to explain the architecture and the product pages to show today’s commercial terms.
Consultation Talking Points
Three explanations that keep the choice clear
“Ellansé S and M are not two strengths of the same filler. They share the same PCL-and-CMC platform, while M is designed for the longer expected duration.”
“Published duration helps us plan the service, but it is not a guarantee of exactly how many months an individual result will remain.”
“The better menu choice is the variant the clinic can explain, document and stock consistently—not automatically the one with the longer name or higher price.”
Professional-use boundary
PCL is not an HA filler with a longer clock
Ellansé is a PCL-based injectable implant, not a hyaluronic-acid filler. Hyaluronidase is used to break down HA and is not an equivalent reversal route for PCL microspheres. Product selection and use belong with trained healthcare professionals working from the current local IFU, client assessment and applicable market requirements.
Frequently asked questions
Questions clinics ask about Ellansé S and M
What is the main difference between Ellansé S and M?
The main documented variant difference is the starting chain length and molecular weight of the PCL polymer. M uses longer PCL chains, which take longer to degrade and support its longer expected duration.
Do Ellansé S and M contain different ingredients?
They use the same core PCL-microsphere and CMC-carrier platform. Published literature commonly describes the platform as 30% PCL microspheres in 70% aqueous CMC gel. Their key product distinction is the PCL chain length, not a different ingredient category.
Is Ellansé M stronger or thicker than Ellansé S?
The letter M should not be used as proof that the product is stronger, thicker or made with larger particles. The manufacturer’s technical explanation connects M with longer PCL chains and longer degradation time.
How long does Ellansé S last compared with M?
A direct 24-month study found sustained improvement for both at 12 months and the longer-lasting result for M through 24 months. Other official summaries include S-specific follow-up at 12–18 months and M-specific evidence at 24 months. These are study observations, not guaranteed individual timelines.
Does Ellansé M automatically belong in deeper treatment areas?
No. A duration code does not by itself establish treatment area or injection depth. Those decisions require the exact current IFU and assessment by an appropriately trained professional.
Should a clinic stock both Ellansé S and M?
Only when the clinic can maintain two distinct duration-led services and enough demand to rotate both SKUs. If the same menu name, explanation and price logic are used for both, one is likely to become duplicate inventory.
Can Ellansé be dissolved like an HA filler?
Not with hyaluronidase. Ellansé is based on PCL microspheres in a CMC carrier rather than hyaluronic acid. This material difference should be part of professional product selection and client expectation setting.
Are Ellansé S and M packaged differently at Cytollia?
Cytollia currently lists both as 2 × 1 mL. The pack format is therefore not the main buying difference. Check the exact live listing and supplied documentation at the time of order because commercial formats can change.
Current Cytollia catalogue
Compare the exact S and M listings
Review current availability, pack details and live tier pricing before ordering. No fixed product price is stored in this editorial page.
Shorter-duration service laneEllansé S · 2 × 1 mLView product and live tier pricing →
Longer-duration service laneEllansé M · 2 × 1 mLView product and live tier pricing →
Current catalogue information may change. The exact variant, supplied box and current documentation should be confirmed at purchase.
Sources and editorial notes
- Ellansé — official frequently asked questions, composition and duration language
- AQTIS Medical / Sinclair — Ellansé Summary of Safety and Clinical Performance
- Ellansé — An Expert’s Guide, PCL degradation and S/M chain-length distinction
- Moers-Carpi and Sherwood — 24-month randomized S/M clinical trial
- de Melo et al. — expert recommendations for PCL-based collagen stimulator use
- Objective assessment of long-term volumizing action of a PCL-based filler
- Retrospective PCL-filler complications study — material persistence and absence of immediate enzymatic removal
Last verified: August 5, 2026. Product platform, current variants, clinical-duration evidence, pack format, availability and live commercial position were checked against the linked manufacturer, clinical and Cytollia catalogue sources. Market indications and supplied documentation may differ by country.
Source context: the expert-recommendation paper includes authors who reported consultancy or other relationships with Sinclair. It is used alongside the legal manufacturer’s SSCP and an independent indexed clinical-trial record rather than as a sole source.
Commercial disclosure: Cytollia sells both products linked in this guide. The comparison is organised around documented variant design and clinic adoption decisions; it does not determine clinical superiority or replace an appropriately qualified professional assessment.